Innoviva and GARDP's breakthrough treatment could become the first new gonorrhea antibiotic in decades amid rising antimicrobial resistance.
Innoviva
Image credits: Innoviva
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zoliflodacin, a novel, first-in-class oral antibiotic developed for the treatment of uncomplicated gonorrhea in adults and adolescents aged 12 years and older. The announcement was made jointly by Innoviva Specialty Therapeutics, Inc, and the Global Antibiotic Research & Development Partnership (GARDP).1
GARDP logo
Image credits: GARDP
If approved, zoliflodacin would be the first new antibiotic for gonorrhea in decades, offering a much-needed alternative amid growing concerns about antimicrobial resistance (AMR).1
Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial sexually transmitted infection worldwide, with more than 82 million new cases annually. Rising resistance to current treatments—particularly ceftriaxone—has become a major public health threat. A recent Phase 3 trial showed that a single oral dose of zoliflodacin was non-inferior to the current standard regimen (an intramuscular ceftriaxone injection followed by a 7-day oral course of azithromycin) in achieving microbiological cure at the urogenital site.1
Zoliflodacin offers a novel, single-dose oral alternative to current injectable therapies, showing non-inferior efficacy in Phase 3 trials.
The drug targets multidrug-resistant Neisseria gonorrhoeae, including strains resistant to ceftriaxone and azithromycin.
The FDA granted zoliflodacin Priority Review and QIDP status, with potential approval expected in Q1 2025.
“Infections resistant to ceftriaxone are emerging globally, and today’s NDA acceptance brings us one step closer to a critical new oral option,” said David Altarac, MD, Chief Medical Officer at Innoviva Specialty Therapeutics.1
The NDA submission is supported by a robust clinical development program carried out under a public-private partnership model with GARDP. In the Phase 3 study, zoliflodacin demonstrated a favorable safety profile, with no serious adverse events or deaths reported.1
Zoliflodacin operates via a unique mechanism of action, targeting bacterial type II topoisomerase—an enzyme essential for bacterial DNA replication. In vitro data show activity against multidrug-resistant strains, including those resistant to both ceftriaxone and azithromycin, with no cross-resistance to other antibiotic classes observed.1
The FDA has designated zoliflodacin a Qualified Infectious Disease Product (QIDP), granting it Priority Review status and Extended Market Exclusivity. Innoviva expects the FDA to follow standard timelines associated with QIDP designations.1
“This important milestone demonstrates the value of public-private partnerships in combating AMR,” said Dr. Manica Balasegaram, Executive Director of GARDP. “Pending approval, zoliflodacin could provide a critical new treatment option globally, particularly in low-resource settings.”1
At IDWeek 2024, Innoviva presented Phase 3 trial data showing zoliflodacin achieved urogenital cure rates of 90.9%, compared to 96.2% for the current standard of care, with good tolerability. The study included patients infected with multidrug-resistant strains, including those carrying the penA 60.001 allele, which confers resistance to ceftriaxone.2
